---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-274327"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:19:31.238958+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma terminates $150M ATM equity offering program

## Summary
- Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.
- Program allowed for sale of up to $150M of ordinary shares.
- No sales will be made under Sales Agreement until new prospectus or registration statement is filed.
- Sales Agreement remains in full force and effect other than the terminated ATM prospectus.

## SEC filing metadata
- accession: 0001193125-24-274327
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/0001193125-24-274327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/d913585d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-274327
- JSON: https://secwatch.observer/filing/0001193125-24-274327.json
- Plain text: https://secwatch.observer/filing/0001193125-24-274327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.